A minimal physiologically based pharmacokinetic model to characterize colon TNF suppression and treatment effects of an anti-TNF monoclonal antibody in a mouse inflammatory bowel disease model.
Inflammatory bowel disease (IBD)
anti-TNF mAb
colon
induction dose
mAb tissue distribution
minimal physiologically based PK (mPBPK) model
pharmacokinetics (PK)
site of action
target engagement (TE)
Journal
mAbs
ISSN: 1942-0870
Titre abrégé: MAbs
Pays: United States
ID NLM: 101479829
Informations de publication
Date de publication:
Historique:
entrez:
24
9
2020
pubmed:
25
9
2020
medline:
13
8
2021
Statut:
ppublish
Résumé
Biotherapeutic drugs against tumor necrosis factor (TNF) are effective treatments for moderate to severe inflammatory bowel disease (IBD). Here, we evaluated CNTO 5048, an antimurine TNF surrogate monoclonal antibody (mAb), in a CD45RB
Identifiants
pubmed: 32967523
doi: 10.1080/19420862.2020.1813962
pmc: PMC7531524
doi:
Substances chimiques
Antibodies, Monoclonal, Murine-Derived
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Video-Audio Media
Langues
eng
Sous-ensembles de citation
IM
Pagination
1813962Références
J Pharmacokinet Pharmacodyn. 2012 Feb;39(1):67-86
pubmed: 22143261
Pathophysiology. 2010 Sep;17(4):315-35
pubmed: 20022228
Clin Pharmacol Ther. 2019 Nov;106(5):945-954
pubmed: 31420861
Biochem J. 1992 Jun 15;284 ( Pt 3):905-10
pubmed: 1622406
Pharm Res. 2016 Apr;33(4):1040-9
pubmed: 26718954
J Clin Pharmacol. 2015 Mar;55 Suppl 3:S75-84
pubmed: 25707966
MAbs. 2011 Jan-Feb;3(1):61-6
pubmed: 20962582
Minerva Gastroenterol Dietol. 2010 Jun;56(2):233-43
pubmed: 20485259
AAPS J. 2009 Jun;11(2):371-80
pubmed: 19452283
J Pharmacokinet Pharmacodyn. 2014 Dec;41(6):571-80
pubmed: 25146360
Front Immunol. 2019 Feb 26;10:308
pubmed: 30863410
J Crohns Colitis. 2016 Aug;10(8):989-97
pubmed: 26896086
BMC Gastroenterol. 2014 Nov 18;14:189
pubmed: 25407511
J Pharmacokinet Pharmacodyn. 2014 Aug;41(4):375-87
pubmed: 25077917
World J Gastroenterol. 2016 Nov 14;22(42):9300-9313
pubmed: 27895418
Am J Physiol Gastrointest Liver Physiol. 2009 Feb;296(2):G135-46
pubmed: 19033538
J Pharmacokinet Pharmacodyn. 2012 Dec;39(6):711-23
pubmed: 23179857
J Inflamm Res. 2018 May 16;11:215-226
pubmed: 29844695
Nat Rev Gastroenterol Hepatol. 2016 Jan;13(1):13-27
pubmed: 26627550
AAPS J. 2018 Apr 17;20(3):63
pubmed: 29667047
J Pharmacokinet Pharmacodyn. 2016 Jun;43(3):291-304
pubmed: 27119518
J Pharmacokinet Pharmacodyn. 2008 Oct;35(5):573-91
pubmed: 19005743
Proc Natl Acad Sci U S A. 2018 Dec 26;115(52):E12313-E12322
pubmed: 30541887
Drug Metab Dispos. 2017 Jul;45(7):790-797
pubmed: 28411280
J Immunol. 1985 Dec;135(6):3972-7
pubmed: 2999236
Exp Dermatol. 2016 Feb;25(2):157-9
pubmed: 26439798
Drug Des Devel Ther. 2015 Jul 21;9:3789-99
pubmed: 26229440
Expert Opin Biol Ther. 2014 May;14(5):569-72
pubmed: 24611432
AAPS J. 2014 Jan;16(1):129-39
pubmed: 24287601
J Pharmacol Exp Ther. 2005 May;313(2):578-85
pubmed: 15647331
Ups J Med Sci. 2015;120(3):135-43
pubmed: 26220421
AAPS J. 2011 Mar;13(1):99-110
pubmed: 21240643
Inflamm Bowel Dis. 2013 Feb;19(2):246-53
pubmed: 22649027
Mucosal Immunol. 2009 May;2(3):220-31
pubmed: 19262505
Expert Rev Gastroenterol Hepatol. 2016 Aug;10(8):915-27
pubmed: 27043489
Cold Spring Harb Perspect Biol. 2014 Oct 23;7(1):a016345
pubmed: 25384307
J Pharmacokinet Pharmacodyn. 2013 Oct;40(5):597-607
pubmed: 23996115
Pharm Res. 2015 Oct;32(10):3269-81
pubmed: 25939552
Clin Microbiol Rev. 2002 Jan;15(1):79-94
pubmed: 11781268
Immunol Ser. 1992;56:3-34
pubmed: 1550865
Curr Gastroenterol Rep. 2016 Oct;18(10):55
pubmed: 27637649
J Pharmacol Exp Ther. 2018 Apr;365(1):140-155
pubmed: 29420255
BioDrugs. 2010 Dec 14;24 Suppl 1:3-14
pubmed: 21175228